Avalo Therapeutics, Inc. - Common Stock (AVTX)
CUSIP: 05338F306
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 22,946,429
- Total 13F shares
- 19,885,517
- Share change
- +4,156,297
- Total reported value
- $361,121,251
- Put/Call ratio
- 59%
- Price per share
- $18.16
- Number of holders
- 84
- Value change
- +$79,863,888
- Number of buys
- 57
- Number of sells
- 27
Quarterly Holders Quick Answers
What is CUSIP 05338F306?
CUSIP 05338F306 identifies AVTX - Avalo Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 05338F306:
Top shareholders of AVTX - Avalo Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
|
Company |
9.9%
|
1,939,065
|
$32,867,152 | +$9,371,621 | 31 Dec 2025 | |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
|
BVF PARTNERS L P/IL |
10%
|
1,904,257
|
$32,277,156 | +$7,561,497 | 31 Dec 2025 | |
| ORBIMED ADVISORS LLC |
13D/G
13F
|
Company |
6.4%
|
1,187,300
|
$20,124,735 | +$3,734,085 | 31 Dec 2025 | |
| BVF INC/IL |
13F
|
Company |
5.9%
|
1,355,256
|
$17,225,304 | — | 30 Sep 2025 | |
| Nantahala Capital Management, LLC |
13D/G
13F
|
Company |
9.4%
|
1,235,000
|
$15,696,850 | +$4,257,850 | 30 Sep 2025 | |
| Caligan Partners LP |
13D/G
13F
|
Company |
4.9%
|
881,533
|
$14,941,984 | +$816,990 | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13D/G
13F
|
The Vanguard Group · Company |
4.4%
|
804,084
|
$14,602,165 | +$2,023,878 | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
13D/G
|
Company |
3.5%
from 13D/G
|
1,053,983
|
$13,396,124 | — | 30 Sep 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
4.4%
|
1,006,217
|
$12,789,018 | — | 30 Sep 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
13D/G
|
Company |
2.4%
from 13D/G
|
817,436
|
$10,389,612 | — | 30 Sep 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
13D/G
|
Company |
2.8%
from 13D/G
|
720,922
|
$9,162,919 | — | 30 Sep 2025 | |
| Ikarian Capital, LLC |
13D/G
13F
|
Company |
3.8%
|
711,967
|
$9,049,101 | -$6,100,673 | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
2.6%
|
605,842
|
$7,700,252 | — | 30 Sep 2025 | |
| Commodore Capital LP |
13F
|
Company |
2.1%
|
483,000
|
$6,138,930 | — | 30 Sep 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
2.1%
|
483,000
|
$6,138,930 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.1%
|
481,669
|
$6,122,013 | — | 30 Sep 2025 | |
| Patrick J. Crutcher |
13D/G
|
— |
4.2%
|
549,467
|
$3,593,514 | $0 | 06 Aug 2025 | |
| Velan Capital Investment Management LP |
13F
|
Company |
1.1%
|
263,642
|
$3,350,890 | — | 30 Sep 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.1%
|
258,769
|
$3,288,954 | — | 30 Sep 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.99%
|
228,297
|
$2,901,655 | — | 30 Sep 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.93%
|
213,572
|
$2,714,500 | — | 30 Sep 2025 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
0.82%
|
188,080
|
$2,390,497 | — | 30 Sep 2025 | |
| Ally Bridge Group (NY) LLC |
13F
|
Company |
0.78%
|
178,100
|
$2,263,651 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.67%
|
154,251
|
$1,960,531 | — | 30 Sep 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
0.63%
|
144,600
|
$1,837,866 | — | 30 Sep 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.61%
|
139,667
|
$1,775,168 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.6%
|
137,431
|
$1,746,748 | — | 30 Sep 2025 | |
| Boxer Capital Management, LLC |
13F
|
Company |
0.54%
|
125,000
|
$1,588,750 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.45%
|
104,189
|
$1,325,396 | — | 30 Sep 2025 | |
| Exome Asset Management LLC |
13F
|
Company |
0.44%
|
100,036
|
$1,271,458 | — | 30 Sep 2025 | |
| Patient Square Capital LP |
13F
|
Company |
0.44%
|
100,000
|
$1,271,000 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.43%
|
98,700
|
$1,254,477 | — | 30 Sep 2025 | |
| RWA WEALTH PARTNERS, LLC |
13F
|
Company |
0.38%
|
86,516
|
$1,099,618 | — | 30 Sep 2025 | |
| CANTOR FITZGERALD, L. P. |
13F
|
Individual |
0.37%
|
85,247
|
$1,083,489 | — | 30 Sep 2025 | |
| DLD Asset Management, LP |
13F
|
Company |
0.33%
|
75,000
|
$953,250 | — | 30 Sep 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.32%
|
72,800
|
$925,288 | — | 30 Sep 2025 | |
| Sio Capital Management, LLC |
13F
|
Company |
0.31%
|
72,173
|
$917,319 | — | 30 Sep 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.24%
|
56,009
|
$711,874 | — | 30 Sep 2025 | |
| Quadrature Capital Ltd |
13F
|
Company |
0.24%
|
54,999
|
$695,737 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.21%
|
49,242
|
$625,866 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.21%
|
47,398
|
$602,429 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.2%
|
45,454
|
$577,720 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.2%
|
45,208
|
$574,594 | — | 30 Sep 2025 | |
| Walleye Capital LLC |
13F
|
Company |
0.19%
|
44,743
|
$568,684 | — | 30 Sep 2025 | |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. |
13F
|
Company |
0.15%
|
33,337
|
$423,713 | — | 30 Sep 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.14%
|
32,393
|
$411,715 | — | 30 Sep 2025 | |
| ARMISTICE CAPITAL, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
765,828
|
$397,771 | — | 26 Jun 2023 | |
| Birchview Capital, LP |
13F
|
Company |
0.14%
|
31,000
|
$394,010 | — | 30 Sep 2025 | |
| HighVista Strategies LLC |
13F
|
Company |
0.12%
|
27,778
|
$353,058 | — | 30 Sep 2025 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.11%
|
24,628
|
$313,022 | — | 30 Sep 2025 |
Institutional Holders of Avalo Therapeutics, Inc. - Common Stock (AVTX) as of Q4 2025
As of 31 Dec 2025,
Avalo Therapeutics, Inc. - Common Stock (AVTX) was held by
84 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,885,517 shares.
The largest 10 holders included
BVF INC/IL, Nantahala Capital Management, LLC, ORBIMED ADVISORS LLC, Affinity Asset Advisors, LLC, Caligan Partners LP, VANGUARD GROUP INC, RA CAPITAL MANAGEMENT, L.P., MILLENNIUM MANAGEMENT LLC, Point72 Asset Management, L.P., and BANK OF AMERICA CORP /DE/.
This page lists
84
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
65
Q4 2025 holders
84
Holder diff
19
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.